Cargando…
Clinicopathologic Features and Radiation Therapy Utilization in Patients with Male Breast Cancer: A National Cancer Database Study
Male breast cancer (MBC) accounts for approximately 1% of all breast cancers, limiting the data characterizing clinicopathologic features and treatment outcomes in patients with MBC. This paucity of data has led to most of our treatment guidance being extrapolated from patients with female breast ca...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987905/ https://www.ncbi.nlm.nih.gov/pubmed/29881286 http://dx.doi.org/10.1177/1178223418770687 |
_version_ | 1783329205493170176 |
---|---|
author | Weir, Joshua Zhao, Yan Daniel Herman, Terence Algan, Özer |
author_facet | Weir, Joshua Zhao, Yan Daniel Herman, Terence Algan, Özer |
author_sort | Weir, Joshua |
collection | PubMed |
description | Male breast cancer (MBC) accounts for approximately 1% of all breast cancers, limiting the data characterizing clinicopathologic features and treatment outcomes in patients with MBC. This paucity of data has led to most of our treatment guidance being extrapolated from patients with female breast cancer (FBC). From 1998 to 2012, data were captured using the National Cancer Database to identify patients with nonmetastatic MBC (n = 23 305) and FBC (n = 2 678 061). Tumor and clinicopathologic features were obtained and compared. Patients with MBC were more likely to have invasive disease, T2-4 tumors, centrally located tumors, positive lymph nodes, estrogen receptor–positive or progesterone receptor–positive tumors, lymphovascular space invasion, and were less likely to have Her2/neu-positive or triple-negative tumors. All of these differences were statistically significant (P < .001). Treatment comparisons showed that patients with MBC were more likely to undergo mastectomy and less likely to undergo breast-conserving surgery with postoperative radiation utilization found to be less in patients with MBC, both as part of breast-conserving therapy (BCT) and for postmastectomy radiation treatment (PMRT) (P < .001). Stage-by-stage comparisons showed that median survival, 5-year, and 10-year overall survival (OS) rates are lower in patients with MBC vs patients with FBC (P < .001). The utilization of adjuvant radiation, both BCT and PMRT, was shown to improve 5- and 10-year OS (P < .001). Male breast cancer clinicopathologic features appear to be unfavorable in relation to FBC and adjuvant radiation is shown beneficial in survival outcomes. Further investigation is needed to help guide future utilization and treatment with radiation, systemic, and endocrine manipulation in this small population of patients with MBC. |
format | Online Article Text |
id | pubmed-5987905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-59879052018-06-07 Clinicopathologic Features and Radiation Therapy Utilization in Patients with Male Breast Cancer: A National Cancer Database Study Weir, Joshua Zhao, Yan Daniel Herman, Terence Algan, Özer Breast Cancer (Auckl) Review Male breast cancer (MBC) accounts for approximately 1% of all breast cancers, limiting the data characterizing clinicopathologic features and treatment outcomes in patients with MBC. This paucity of data has led to most of our treatment guidance being extrapolated from patients with female breast cancer (FBC). From 1998 to 2012, data were captured using the National Cancer Database to identify patients with nonmetastatic MBC (n = 23 305) and FBC (n = 2 678 061). Tumor and clinicopathologic features were obtained and compared. Patients with MBC were more likely to have invasive disease, T2-4 tumors, centrally located tumors, positive lymph nodes, estrogen receptor–positive or progesterone receptor–positive tumors, lymphovascular space invasion, and were less likely to have Her2/neu-positive or triple-negative tumors. All of these differences were statistically significant (P < .001). Treatment comparisons showed that patients with MBC were more likely to undergo mastectomy and less likely to undergo breast-conserving surgery with postoperative radiation utilization found to be less in patients with MBC, both as part of breast-conserving therapy (BCT) and for postmastectomy radiation treatment (PMRT) (P < .001). Stage-by-stage comparisons showed that median survival, 5-year, and 10-year overall survival (OS) rates are lower in patients with MBC vs patients with FBC (P < .001). The utilization of adjuvant radiation, both BCT and PMRT, was shown to improve 5- and 10-year OS (P < .001). Male breast cancer clinicopathologic features appear to be unfavorable in relation to FBC and adjuvant radiation is shown beneficial in survival outcomes. Further investigation is needed to help guide future utilization and treatment with radiation, systemic, and endocrine manipulation in this small population of patients with MBC. SAGE Publications 2018-04-20 /pmc/articles/PMC5987905/ /pubmed/29881286 http://dx.doi.org/10.1177/1178223418770687 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Weir, Joshua Zhao, Yan Daniel Herman, Terence Algan, Özer Clinicopathologic Features and Radiation Therapy Utilization in Patients with Male Breast Cancer: A National Cancer Database Study |
title | Clinicopathologic Features and Radiation Therapy Utilization in
Patients with Male Breast Cancer: A National Cancer Database
Study |
title_full | Clinicopathologic Features and Radiation Therapy Utilization in
Patients with Male Breast Cancer: A National Cancer Database
Study |
title_fullStr | Clinicopathologic Features and Radiation Therapy Utilization in
Patients with Male Breast Cancer: A National Cancer Database
Study |
title_full_unstemmed | Clinicopathologic Features and Radiation Therapy Utilization in
Patients with Male Breast Cancer: A National Cancer Database
Study |
title_short | Clinicopathologic Features and Radiation Therapy Utilization in
Patients with Male Breast Cancer: A National Cancer Database
Study |
title_sort | clinicopathologic features and radiation therapy utilization in
patients with male breast cancer: a national cancer database
study |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987905/ https://www.ncbi.nlm.nih.gov/pubmed/29881286 http://dx.doi.org/10.1177/1178223418770687 |
work_keys_str_mv | AT weirjoshua clinicopathologicfeaturesandradiationtherapyutilizationinpatientswithmalebreastcanceranationalcancerdatabasestudy AT zhaoyandaniel clinicopathologicfeaturesandradiationtherapyutilizationinpatientswithmalebreastcanceranationalcancerdatabasestudy AT hermanterence clinicopathologicfeaturesandradiationtherapyutilizationinpatientswithmalebreastcanceranationalcancerdatabasestudy AT alganozer clinicopathologicfeaturesandradiationtherapyutilizationinpatientswithmalebreastcanceranationalcancerdatabasestudy |